Filing Details
- Accession Number:
- 0000899243-22-012991
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-31 20:15:32
- Reporting Period:
- 2022-03-29
- Accepted Time:
- 2022-03-31 20:15:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1880438 | An2 Therapeutics Inc. | ANTX | Pharmaceutical Preparations (2834) | 820606654 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1914883 | Shane Robin Readnour | C/O Mountain Group Capital, Llc 3835 Cleghorn Avenue, Suite 300 Nashville TN 37215 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-29 | 285,156 | $0.00 | 285,156 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2022-03-29 | 333,135 | $0.00 | 333,135 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2022-03-29 | 61,491 | $0.00 | 346,647 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2022-03-29 | 71,839 | $0.00 | 404,974 | No | 4 | C | Indirect | See footnotes |
| Common Stock | Acquisiton | 2022-03-29 | 70,716 | $15.00 | 417,363 | No | 4 | P | Indirect | See footnotes |
| Common Stock | Acquisiton | 2022-03-29 | 82,618 | $15.00 | 487,592 | No | 4 | P | Indirect | See footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnotes |
| No | 4 | C | Indirect | See footnotes |
| No | 4 | C | Indirect | See footnotes |
| No | 4 | C | Indirect | See footnotes |
| No | 4 | P | Indirect | See footnotes |
| No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2022-03-29 | 285,156 | $0.00 | 285,156 | $0.00 |
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2022-03-29 | 333,135 | $0.00 | 333,135 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2022-03-29 | 61,491 | $0.00 | 61,491 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2022-03-29 | 71,839 | $0.00 | 71,839 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
- Shares held directly by MGC Venture Partners 2018, LP. ("MGC 2018 LP").
- Shares held directly by MGC Venture Partners QP 2018 LP ("MGC 2018 QP").
- MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
Billionaire Hedge Funds
